1-5 of 5
Marco Wachtel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma

Lieke Mous, Michelle Hofer, Dorita Zabėlė, Ingrid Bechtold, Sakina Zaidi, Camille Fouassier, Pierre Gestraud, Aurélien Boré, Raphaël Margueron, Marco Wachtel, Beat Schäfer, Olivier Delattre, Didier Surdez
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): A009.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-A009
Published: 10 June 2024
View article titled, Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma
Journal Articles

Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer

Sara G. Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier Delattre, Peter K. Bode, Marco Wachtel, Beat W. Schäfer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6): 864–876.
https://doi.org/10.1158/1535-7163.MCT-23-0285
Published: 04 June 2024
View article titled, Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer
Open the PDF for Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer in another window
Includes: Supplementary data
Journal Articles

Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

Fabian F. Pusch, Heathcliff Dorado García, Robin Xu, Dennis Gürgen, Yi Bei, Lotte Brückner, Claudia Röefzaad, Jennifer von Stebut, Victor Bardinet, Rocío Chamorro Gonzalez, Angelika Eggert, Johannes H. Schulte, Patrick Hundsdörfer, Georg Seifert, Kerstin Haase, Beat W. Schäfer, Marco Wachtel, Anja A. Kühl, Michael V. Ortiz, Antje M. Wengner, Monika Scheer, Anton G. Henssen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (4): 507–519.
https://doi.org/10.1158/1535-7163.MCT-23-0094
Published: 02 April 2024
View article titled, Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Open the PDF for Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract C113: p21 downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by histone deacetylase inhibitors enhances combination treatment

Regina Hecker, Ralf A. Amstutz, Marco Wachtel, Dagmar Walter, Felix K. Niggli, Beat W. Schafer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C113.
https://doi.org/10.1158/1535-7163.TARG-09-C113
Published: 10 December 2009
View article titled, Abstract C113: p21 downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by histone deacetylase inhibitors enhances combination treatment
Journal Articles

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma

Susanne Oesch, Dagmar Walter, Marco Wachtel, Kathya Pretre, Maria Salazar, Manuel Guzmán, Guillermo Velasco, Beat W. Schäfer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1838–1845.
https://doi.org/10.1158/1535-7163.MCT-08-1147
Published: 14 July 2009
View article titled, Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma
Open the PDF for Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma in another window